Symbicort brought in worldwide sales of $2.7 billion last year, with $1.1 billion of that coming from the US market, where an authorised generic sold under license from AZ has been available since ...

A US court has upheld AstraZeneca’s patents on its respiratory drug Symbicort, blocking cheaper competition for the ageing blockbuster. The US District Court for the Northern District of West ...

The cap is effective June 1 and will apply to the company’s entire range of inhaler products used to treat asthma and chronic obstructive pulmonary disease, including inhalers Symbicort ...